drugset
drugset / Trial / NCT06833281

Extension Study of Participants From SPG302-ALZ-101

NCT06833281 ↗

Phase 2 Terminated 12 enrolled Spinogenix
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the long-term safety and efficacy of participants enrolled in SPG302-ALZ-101 with mild to moderate Alzheimer's Disease (AD)

Timeline

Start
2025-03-25
Primary completion
2025-07-30
Completion
2025-10-09

Outcome

Outcome not reported

Stopped: “patients treated on compassionate use program”

Drugs

EvaluationDrugModalityDoseRoute
Subject SPG302 Small molecule — Oral

Indications

Alzheimer disease